Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Check-Cap Ltd (CHEK) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/04/2023 6-K Quarterly results
Docs: "6-K",
"Check-Cap Reports Second Quarter 2023 Financial Results",
"Consolidated Unaudited Financial Statements as of June 30, 2023"
11/03/2021 6-K Quarterly results
Docs: "6-K",
"Check-Cap Reports Third Quarter 2021 Financial Results and Corporate Update"
05/12/2021 6-K Quarterly results
08/06/2020 6-K Quarterly results
11/06/2019 6-K Quarterly results
08/07/2019 6-K Quarterly results
Docs: "6-K",
"Check-Cap Reports Second Quarter 2019 Financial Results and Corporate Highlights",
"Consolidated Financial Statements as of June 30, 2019 (Unaudited)"
05/13/2019 6-K Quarterly results
Docs: "6-K",
"Check-Cap Reports First Quarter 2019 Financial Results",
"Check-Cap Announces Second Trial Site Joins Ongoing U.S. Pilot Study of C-Scan® Mayo Clinic joins New York University in pilot study of C-Scan® in the U.S. ISFIYA, Israel, May 13, 2019 /PRNewswire/ -- Check-Cap Ltd. , , a clinical-stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free ingestible capsule for the prevention of colorectal cancer through the detection of precancerous polyps, today announced that Mayo Clinic is the second trial site participating in the Company's ongoing pilot study of the C-Scan® system in the U.S. "We are thrilled to collaborate with Mayo Clinic as a part of our U.S. pilot study of the C-Scan® system," commented Alex Ovadia, chief executive officer of Check-Cap. "Together with the continued progress being ..."
11/05/2018 6-K Quarterly results
Docs: "6-K",
"Check-Cap Reports Third Quarter 2018 Financial Results Announced Interim Results from Post-CE Approval Study of C-Scan® Announces Update on Scheduled Initiation of U.S. Pilot Study ISFIYA, Israel, Nov. 5, 2018 /PRNewswire/ -- Check-Cap Ltd. , , a clinical-stage medical diagnostics company engaged in the development of C-Scan®, a preparation free capsule-based screening method for the prevention of colorectal cancer through the detection of precancerous polyps, announced today financial results for the third quarter and nine months ended September 30, 2018. Recent Highlights · Submitted an Investigational Device Exemption to the U.S. Food and Drug Administration that, if approved, would allow the Company to initiate a U.S. pilot study of the C-Scan system by the end of 2018, in collaborati..."
07/31/2018 6-K Quarterly results
Docs: "6-K",
"Check-Cap Reports Second Quarter 2018 Financial Results",
"Consolidated Financial Statements as of June 30, 2018 (Unaudited)"
05/17/2018 6-K Quarterly results
Docs: "6-K",
"Check-Cap Reports First Quarter 2018 Financial Results"
04/04/2018 6-K Quarterly results
Docs: "6-K",
"Check-Cap Reports Fourth Quarter and Full Year 2017 Financial Results Announces the achievement of key validation milestones in C-Scan ® system clinical and regulatory pathway"
11/06/2017 6-K Quarterly results
Docs: "6-K",
"Check-Cap Reports Third Quarter 2017 Financial Results ISFIYA, Israel and BOSTON, Nov. 6, 2017 /PRNewswire/ -- Check-Cap Ltd. , a clinical-stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule for preparation-free, colorectal cancer screening, today announced its financial results for the third quarter and nine months ended September 30, 2017. Recent Highlights Continued advancements on C-Scan regulatory, clinical performance, and development programs: · Filed CE Mark registration for the C-Scan system. Data from the multi-center clinical safety and performance study to support the submission showed safety and encouraging results for detecting patients with polyps in an un-prepped colon. Data from the study demonstrated a 44% sensitivity for patient..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy